NCT07295483 Predictors of Long-Term Evolution in Long COVID; 4-Year Follow-Up. (BioICOPER Follow-up Study)
| NCT ID | NCT07295483 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Instituto de Investigación Biomédica de Salamanca |
| Condition | Persistent COVID Condition |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2026-02-09 |
| Primary Completion | 2029-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2026-02-09 with a primary completion date of 2029-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Long COVID (persistent COVID) represents a major global health challenge due to its high prevalence (approximately 7%), significant impact on quality of life, and socioeconomic burden. Despite extensive research, diagnostic tools to objectively identify or predict long COVID evolution are still lacking. The BioICOPER Follow-up Study aims to analyze the influence of biomarker evolution on clinical symptomatology (particularly chronic fatigue) and vascular health after four years of follow-up among 400 participants previously included in the original BioICOPER cohort. Advanced proteomic analysis, vascular function assessment, and machine-learning-based predictive modeling will be used to identify biomarkers associated with disease progression, stratified by sex. This project will contribute to personalized clinical management of long COVID and improved diagnostic and therapeutic strategies in primary care.
Eligibility Criteria
Inclusion Criteria: * Adults ≥18 years old. * Confirmed previous SARS-CoV-2 infection. * Diagnosis of long COVID according to WHO criteria. * Participation in the baseline BioICOPER study. * Signed informed consent for re-evaluation. Exclusion Criteria: * Acute illness preventing participation. * Cognitive or physical impairment limiting data collection. * Withdrawal of informed consent. * Age \< 18 years old
Contact & Investigator
Manuel Angel Gomez Marcos, MD, PhD
PRINCIPAL INVESTIGATOR
Centro Asistencial Universitario de Salamanca (CAUSA)
Frequently Asked Questions
Who can join the NCT07295483 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Persistent COVID Condition. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07295483 currently recruiting?
Yes, NCT07295483 is actively recruiting participants. Contact the research team at magomez@usal.es for enrollment information.
Where is the NCT07295483 trial being conducted?
This trial is being conducted at Salamanca, Spain.
Who is sponsoring the NCT07295483 clinical trial?
NCT07295483 is sponsored by Instituto de Investigación Biomédica de Salamanca. The principal investigator is Manuel Angel Gomez Marcos, MD, PhD at Centro Asistencial Universitario de Salamanca (CAUSA). The trial plans to enroll 400 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.